ERBB3 expression
|
HER2 Positive Breast Cancer
|
ERBB3 expression
|
HER2 Positive Breast Cancer
|
ado-trastuzumab emtansine Sensitive: B - Late Trials
|
ado-trastuzumab emtansine Sensitive: B - Late Trials
|
ERBB3 expression
|
CRC
|
ERBB3 expression
|
CRC
|
U3-1402 Sensitive: C2 – Inclusion Criteria
|
U3-1402 Sensitive: C2 – Inclusion Criteria
|
ERBB3 expression
|
Breast Cancer
|
ERBB3 expression
|
Breast Cancer
|
U3-1402 Sensitive: C2 – Inclusion Criteria
|
U3-1402 Sensitive: C2 – Inclusion Criteria
|
ERBB3 expression
|
CRC
|
ERBB3 expression
|
CRC
|
cetuximab Sensitive: C3 – Early Trials
|
cetuximab Sensitive: C3 – Early Trials
|
ERBB3 expression
|
Endometrial Cancer
|
ERBB3 expression
|
Endometrial Cancer
|
lapatinib Resistant: D – Preclinical
|
lapatinib Resistant: D – Preclinical
|
ERBB3 expression
|
Bladder Cancer
|
ERBB3 expression
|
Bladder Cancer
|
lapatinib Resistant: D – Preclinical
|
lapatinib Resistant: D – Preclinical
|
ERBB3 expression
|
Melanoma
|
ERBB3 expression
|
Melanoma
|
U3-1402 Sensitive: D – Preclinical
|
U3-1402 Sensitive: D – Preclinical
|
ERBB3 expression
|
Pancreatic Cancer
|
ERBB3 expression
|
Pancreatic Cancer
|
afatinib Sensitive: D – Preclinical
|
afatinib Sensitive: D – Preclinical
|
ERBB3 expression
|
Pancreatic Cancer
|
ERBB3 expression
|
Pancreatic Cancer
|
pertuzumab Sensitive: D – Preclinical
|
pertuzumab Sensitive: D – Preclinical
|
ERBB3 expression
|
Estrogen Receptor Positive Breast Cancer
|
ERBB3 expression
|
Estrogen Receptor Positive Breast Cancer
|
U3-1402 Sensitive: D – Preclinical
|
U3-1402 Sensitive: D – Preclinical
|